Enlivex Ends $200M+ Private Placement After Rain Foundation Deal Termination

Enlivex Ltd., a NASDAQ-listed biotech focused on longevity and immunotherapy, has terminated a $66.67 million private placement deal with Rain Foundation, citing failure to secure shareholder approval. The transaction, originally intended to sell 66,666,667 ordinary shares, was to be funded via Rain tokens. The company exercised its termination rights under the securities purchase agreement, thereby abandoning the planned transaction and avoiding the need for further shareholder votes. Enlivex, based in Nes-Ziona, Israel, operates under the ticker ENLV and is developing Allocetra, a clinical-stage immunotherapy targeting age-related inflammatory conditions, including osteoarthritis. The company also employs a prediction markets treasury strategy via the Rain protocol on Arbitrum, a decentralized infrastructure for financial instruments.